Perspective Therapeutics (NYSE:CATX) Given New $15.00 Price Target at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its target price reduced by Royal Bank of Canada from $16.00 to $15.00 in a research note released on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

CATX has been the topic of a number of other reports. Scotiabank began coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 19th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Trading Down 4.3 %

Shares of NYSE:CATX opened at $2.20 on Thursday. The business’s 50 day moving average price is $2.94 and its 200-day moving average price is $6.36. Perspective Therapeutics has a 1 year low of $2.19 and a 1 year high of $19.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Perspective Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock worth $224,000 after buying an additional 11,472 shares in the last quarter. Velan Capital Investment Management LP purchased a new position in shares of Perspective Therapeutics in the 4th quarter worth about $1,595,000. Squarepoint Ops LLC purchased a new stake in Perspective Therapeutics during the fourth quarter worth approximately $626,000. Wexford Capital LP acquired a new stake in Perspective Therapeutics in the 4th quarter valued at $64,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $484,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.